Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
about
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerHow do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experimentGenomic profiling in luminal breast cancerClinicians' expectations for gene-driven cancer therapyAdjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10).Breast cancer: Actual methods of treatment and future trends.The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical DecisionsThe clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.Impact of multigene assays in early stage breast cancer.Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyPsychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS.Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast CancerThe value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceThe 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyRacial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K.The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Gene expression profiling: changing face of breast cancer classification and management.The impact of the 21-gene assay on adjuvant treatment decisions in oestrogen receptor-positive early breast cancer: a prospective study.Breast Cancer Biomarkers: Utility in Clinical Practice.Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.Patterns of 21-gene assay testing and chemotherapy use in black and white breast cancer patients.Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review.The application of Oncotype DX in early-stage lymph-node-positive disease.Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis.Gene-Expression-Based Predictors for Breast Cancer.21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.GENE EXPRESSION PROFILING AND EXPANDED IMMUNOHISTOCHEMISTRY TESTS TO GUIDE SELECTION OF CHEMOTHERAPY REGIMENS IN BREAST CANCER MANAGEMENT: A SYSTEMATIC REVIEW.An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.Breast carcinoma with an Oncotype Dx recurrence score <18: Rate of distant metastases in a large series with clinical follow-up.Long-term cost-effectiveness of Oncotype DX® versus current clinical practice from a Dutch cost perspective.Using a gene expression signature when controversy exists regarding the indication for adjuvant systemic treatment reduces the proportion of patients receiving adjuvant chemotherapy: a nationwide study.Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry.Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
P2860
Q21089802-E11CE7D2-4478-4F62-8E01-E9F3B1D1DF96Q24658523-03994A9E-EF61-4FAF-A5DC-30B2D313BD42Q26862681-683E193D-37C4-4A04-9251-D3F75F2FB049Q28083844-B15745C2-72EB-4262-83A8-9CDEAAD7C695Q33560459-2CE2983A-33B3-4B65-ACAA-66103AD2F1F4Q33751802-EAA0719D-1537-4A42-B723-8040874354DFQ34797928-C9B63700-B543-481E-9D8F-1D7BE69E70F2Q35430076-467A6336-2C23-4151-B1BC-A04F9C5649D6Q35599759-0BEAE25D-0EF8-45CF-B53D-2AD788DC6ECFQ35915708-D867265A-E9C5-4446-9D2C-612B483F7E24Q36147839-F691D185-7591-4918-883E-49DC3D712CD3Q36279583-C80CCEDF-4310-44CA-BC55-3A7DA0A63C4BQ36462893-E580B65C-E93F-473E-95CC-64F8B3D0E362Q36615770-41593F60-9AA1-4765-8F8D-6EFEF818962EQ36678505-6F373A53-02B7-44ED-B18E-FC5E3B527F38Q36914381-DB080EC1-1928-46C6-B055-585510D9E93FQ36924703-B5A6F7A7-C28F-4C2E-A358-9B3D2030CAB6Q36997719-9396EF79-1C5A-48CD-9609-9AEC753F01C1Q37138266-4BDBB834-4AB7-4A85-9EA3-C8717A0C426DQ37169835-E491420B-8FAA-4A17-9F12-29B732861CC2Q37174950-B0E824EF-3C3B-4006-BA26-C2144E1B9907Q37441159-E5167263-EA15-4EE0-A79E-1C000401F45FQ37586558-EBB2C670-F74E-4D64-95F6-E28FBD101E4DQ37606937-36630B97-40BF-446D-9924-D9E8E3D59AAAQ38048818-927BF88A-C417-4F8A-B40A-B09BC6945051Q38180001-9B7514F8-79BC-43D9-B3B3-CB799AF01154Q38232507-C51821DB-24F7-4BC5-90F5-D14F54AE2E65Q38540963-DAA748D3-E9BC-4168-9E2E-86578A1AC2B9Q38555220-CB085179-A1D7-4227-931B-21F9A87B2152Q38681547-65E5DF19-8A80-44E9-8BA3-DB801DAC33D1Q38747402-2192ED29-E2EA-433B-B694-CFB98EBBE7FCQ38795484-E9DB5318-13E4-4420-8167-1FD5D828D57AQ39015485-CA230498-B080-46A1-9BCF-AB325EAD4131Q39106167-5519B3D9-1011-48C2-B611-BDAFDCCF4096Q39489143-E541A720-34EE-4C9D-8C34-3A6402076FB1Q41075349-2485188E-4C75-4534-BA95-2ACFC2B79549Q41113513-BD5D7F19-3B01-45A0-9E69-F270C90303E7Q41367403-C2FEC2E1-1E3E-4B1D-93FA-9B18C11991E8Q41481374-88B7397B-90A8-4D41-B76B-6C462F82EDEAQ47204606-BC3121C6-0B71-4F4D-AE56-CB8EA3A34FB2
P2860
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Prospective transGEICAM study ...... ) node-negative breast cancer.
@ast
Prospective transGEICAM study ...... ) node-negative breast cancer.
@en
Prospective transGEICAM study ...... ith estrogen receptor-positive
@nl
type
label
Prospective transGEICAM study ...... ) node-negative breast cancer.
@ast
Prospective transGEICAM study ...... ) node-negative breast cancer.
@en
Prospective transGEICAM study ...... ith estrogen receptor-positive
@nl
prefLabel
Prospective transGEICAM study ...... ) node-negative breast cancer.
@ast
Prospective transGEICAM study ...... ) node-negative breast cancer.
@en
Prospective transGEICAM study ...... ith estrogen receptor-positive
@nl
P2093
P2860
P50
P356
P1433
P1476
Prospective transGEICAM study ...... +) node-negative breast cancer
@en
P2093
A González
I Tusquets
J Albanell
J M Corominas
P2860
P304
P356
10.1093/ANNONC/MDR278
P577
2011-06-06T00:00:00Z